TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7762773

Group type: EXPERIMENTAL
Intervention: Group 1 (constant minute ventilation)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Group 2 (minute ventilation increased to keep paCO2 constant)
Number of subjects: 44
Study: 1967767

Group type: EXPERIMENTAL
Intervention: B9AspB27Glu
Number of subjects: 6

Group type: COMPARATOR
Intervention: Actrapid HM U100
Number of subjects: 6
Study: 7064876

Group type: EXPERIMENTAL
Intervention: Test meal rich in phosphatidylcholine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control meal low in phosphatidylcholine
Number of subjects: 6
Study: 30758076

Group type: EXPERIMENTAL
Intervention: 0.3% rhFGF-2 + DBBM (test)
Number of subjects: 44

Group type: COMPARATOR
Intervention: rhFGF-2 alone (control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 28168555

Group type: EXPERIMENTAL
Intervention: HImax (80% 1RM)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LOmax (40% 1RM preceded by 60 repetitions at 20-25% 1RM)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LO (40% 1RM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Overall (all groups)
Number of subjects: 36

Group type: COMPARATOR
Intervention: sTNFR1 and IL-1RA
Number of subjects: 36

Group type: COMPARATOR
Intervention: IL-1beta, IL-10, GM-CSF
Number of subjects: 36
Study: 26709238

Group type: EXPERIMENTAL
Intervention: Nicotine patch 10 mg/16 hr for 8 weeks
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Nicotine patch 15 mg/16 hr for 8 weeks
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Varenicline for 12 weeks
Number of subjects: 291
Study: 24157951

Group type: EXPERIMENTAL
Intervention: Aqualase
Number of subjects: 100

Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 100
Study: 22654429

Group type: COMPARATOR
Intervention: 7-day conventional triple therapy
Number of subjects: 460

Group type: COMPARATOR
Intervention: 10-day conventional triple therapy
Number of subjects: 460

Group type: COMPARATOR
Intervention: 14-day conventional triple therapy
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy
Number of subjects: 460
Study: 19464125

Group type: EXPERIMENTAL
Intervention: Hydromorphone (HYD) 12 mg IM
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hydromorphone (HYD) 24 mg IM
Number of subjects: 13

Group type: COMPARATOR
Intervention: Money reinforcement ($2 or $4)
Number of subjects: 13
Study: 17364587

Group type: EXPERIMENTAL
Intervention: Morning dosing of olmesartan (20 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Evening dosing of olmesartan (20 mg)
Number of subjects: 18
Study: 15164513

Group type: EXPERIMENTAL
Intervention: Combination of antianginal drugs and membran‐oprotective drugs (MPD)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Antianginal drugs alone
Number of subjects: 59
Study: 11136274

Group type: EXPERIMENTAL
Intervention: naproxen (500-1000 mg/day) and misoprostol (200 microg b.d.)
Number of subjects: 90

Group type: COMPARATOR
Intervention: nabumetone (1000-1500 mg/day) and placebo misoprostol
Number of subjects: 90
Study: 9589757

Group type: EXPERIMENTAL
Intervention: Assertive community treatment (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard case management (SCM)
Number of subjects: 0
Study: 8045844

Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 11
Study: 2927553

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase with 5 X 10(5) IU (SK‐i.v.) in group A before transport
Number of subjects: 76

Group type: COMPARATOR
Intervention: Intravenous streptokinase with 5 X 10(5) IU (SK‐i.v.) in group B after transport
Number of subjects: 76
Study: 30894394

Group type: EXPERIMENTAL
Intervention: Self-injection training for DMPA-SC
Number of subjects: 731

Group type: COMPARATOR
Intervention: Provider-administered DMPA-SC
Number of subjects: 731
Study: 28219801

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) - 10 cycles, using DIOMED Light or PhotoDYN Light
Number of subjects: 100
Study: 25189167

Group type: EXPERIMENTAL
Intervention: Lactate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: β-hydroxybutyrate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 35
Study: 23312939

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of calf muscles at 60 bpm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of calf muscles at 75 bpm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of calf muscles at 86 bpm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of calf muscles at 100 bpm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of calf muscles
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline measurements before stimulation
Number of subjects: 15
Study: 21681863

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (TAPS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 40
Study: 19332194

Group type: EXPERIMENTAL
Intervention: Invasive strategy post-fibrinolysis (n = 1,583)
Number of subjects: 3153

Group type: COMPARATOR
Intervention: Conservative strategy post-fibrinolysis (n = 1,570)
Number of subjects: 3153

Group type: EXPERIMENTAL
Intervention: Group 5 (highest TRI risk)
Number of subjects: 3153

Group type: EXPERIMENTAL
Intervention: Group 4
Number of subjects: 3153

Group type: EXPERIMENTAL
Intervention: Group 3
Number of subjects: 3153

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3153
Study: 16378915

Group type: EXPERIMENTAL
Intervention: Green tea capsules
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 12946074

Group type: EXPERIMENTAL
Intervention: Silica-coated ceramic surface with Panavia 21 and silane/bonding agent
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Silica-coated ceramic surface with Panavia 21 without silanization
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Untreated ceramic surface with Panavia 21 and silane/bonding agent
Number of subjects: 100

Group type: COMPARATOR
Intervention: Untreated ceramic surface with Panavia 21 without silanization (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Silica-coated ceramic surface with RelyX ARC
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Untreated ceramic surface with RelyX ARC
Number of subjects: 100
Study: 11776174

Group type: EXPERIMENTAL
Intervention: One antibiotic given for three days (group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Only once antibiotic used (group C)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No antibiotic given (group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both cesarean section and antibiotics
Number of subjects: 45
Study: 9049798

Group type: COMPARATOR
Intervention: Free gingival grafts (Group A)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Subpedicle grafts (Group B)
Number of subjects: 70
Study: 8383058

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg x 2
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propranolol 80 mg x 2 (in reference group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg x 2
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg x 3
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo x 2
Number of subjects: 60
Study: 3087862

Group type: EXPERIMENTAL
Intervention: Interferon (5 X 10(6) IU) administered once daily subcutaneously during a five day treatment period followed by a three month maintenance period (1 X 10(6) IU three times weekly)
Number of subjects: 31
Study: 31795756

Group type: EXPERIMENTAL
Intervention: JNFS loaded with buffered 1% lidocaine
Number of subjects: 28

Group type: COMPARATOR
Intervention: JNFS loaded with sterile normal saline (Control)
Number of subjects: 28
Study: 29109117

Group type: EXPERIMENTAL
Intervention: sulindac and erlotinib
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 27616435

Group type: EXPERIMENTAL
Intervention: Xenogeneic collagen matrix (XCM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (untreated site)
Number of subjects: 20
Study: 25574960

Group type: EXPERIMENTAL
Intervention: Stavudine
Number of subjects: 2895

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 2895

Group type: EXPERIMENTAL
Intervention: Didanosine
Number of subjects: 2895

Group type: EXPERIMENTAL
Intervention: Weight at ART initiation
Number of subjects: 2895

Group type: EXPERIMENTAL
Intervention: Age at ART initiation
Number of subjects: 2895

Group type: COMPARATOR
Intervention: Sex
Number of subjects: 2895

Group type: COMPARATOR
Intervention: CD4(+) cell count
Number of subjects: 2895

Group type: COMPARATOR
Intervention: CD4(+) cell count monitoring
Number of subjects: 2895
Study: 23292622

Group type: EXPERIMENTAL
Intervention: Buspirone (20-30 mg/day depending on weight)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methylphenidate (20-30 mg/day depending on weight)
Number of subjects: 40
Study: 20100371

Group type: EXPERIMENTAL
Intervention: alpha‐rhamnosidase‐treated orange juice
Number of subjects: 16

Group type: COMPARATOR
Intervention: untreated orange juice
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: orange juice fortified with three times the original content of hesperetin‐7‐O‐rutinoside
Number of subjects: 16
Study: 18756812

Group type: EXPERIMENTAL
Intervention: Ozeltamivir (Tamiflu)
Number of subjects: 0
Study: 15699292

Group type: EXPERIMENTAL
Intervention: DHEA therapy (90 mg/d for 3 weeks and 450 mg/d for 3 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: DHEA therapy
Number of subjects: 46
Study: 12022530

Group type: EXPERIMENTAL
Intervention: Ultrasonically skeletonized graft (group S)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Pedicle harvesting (group P)
Number of subjects: 65
Study: 18425654

Group type: EXPERIMENTAL
Intervention: Tobacco cessation intervention delivered by dental hygienists during cleaning visits; specific components included video and written materials; details on dosage and duration not specified.
Number of subjects: 633

Group type: COMPARATOR
Intervention: Usual care (control group); no specific intervention details provided.
Number of subjects: 633
Study: 8729141

Group type: COMPARATOR
Intervention: Fish Diet (FD)
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Fish Diet (FD) subgroup (n = 61)
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Fish Diet (FD) subgroup
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Vegetarian Diet (VD) subgroup (n = 55)
Number of subjects: 1236
Study: 1717688

Group type: EXPERIMENTAL
Intervention: Sustained release formulation of tiaprofenic acid (two 300 mg capsules once a day)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard formulation of tiaprofenic acid (one 300 mg tablet taken twice a day)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 119
Study: 6211228

Group type: EXPERIMENTAL
Intervention: aminoglutethimide-hydrocortisone
Number of subjects: 122

Group type: COMPARATOR
Intervention: placebo aminoglutethimide-placebo hydrocortisone
Number of subjects: 122
Study: 31111516

Group type: EXPERIMENTAL
Intervention: Online information and support programme
Number of subjects: 61
Study: 27548912

Group type: EXPERIMENTAL
Intervention: Hands-on training with cadaveric simulations (Group A)
Number of subjects: 30
Study: 25959502

Group type: EXPERIMENTAL
Intervention: Family Motivational Intervention (FMI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Routine Family Support (RFS)
Number of subjects: 75
Study: 23944194

Group type: EXPERIMENTAL
Intervention: Armodafinil
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 21433021

Group type: EXPERIMENTAL
Intervention: VR simulator
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional teaching methods
Number of subjects: 20
Study: 19646195

Group type: EXPERIMENTAL
Intervention: GlucoWatch G2 Biographer
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: MiniMed continuous glucose monitoring system (CGMS)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 404

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 404
Study: 17917317

Group type: EXPERIMENTAL
Intervention: Valsartan (40‐80 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nifedipine (20‐40 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (age- and gender-matched subjects without hypertension)
Number of subjects: 16
Study: 15040652

Group type: EXPERIMENTAL
Intervention: Enhanced pharmacist care
Number of subjects: 675

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 675
Study: 12536287

Group type: EXPERIMENTAL
Intervention: Serum uric acid (UA) levels in MS patients
Number of subjects: 124

Group type: COMPARATOR
Intervention: Serum uric acid (UA) levels in controls
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Correlation of UA levels with disease activity, duration, disability, or course in MS patients
Number of subjects: 124
Study: 9620489

Group type: EXPERIMENTAL
Intervention: Topical agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stripping control
Number of subjects: 0
Study: 7882454

Group type: EXPERIMENTAL
Intervention: Oral amiodarone (600-800 mg daily) with infusional doxorubicin (60 mg/m2 over 96 h)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oral amiodarone (600-800 mg daily) with infusional vinblastine (8.5 mg/m2 over 120 h)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pgp expression
Number of subjects: 33
Study: 2142915

Group type: EXPERIMENTAL
Intervention: Ipratropium (80 micrograms via metered dose inhaler with each salbutamol treatment, 6 to 8 times per day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (via metered dose inhaler with each salbutamol treatment, 6 to 8 times per day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ipratropium (for patients with asthma)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (for patients with asthma)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ipratropium (for patients with COPD)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (for patients with COPD)
Number of subjects: 68
Study: 599799

Group type: EXPERIMENTAL
Intervention: Visken (prindolol)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 31951150

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30316635

Group type: EXPERIMENTAL
Intervention: <350 mg/dL (moderate control)
Number of subjects: 110

Group type: COMPARATOR
Intervention: <600 mg/dL (loose control)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Repeat ED visits for hyperglycemia
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Hospitalization for hyperglycemia
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Hospitalization for any reason
Number of subjects: 110
Study: 26364686

Group type: EXPERIMENTAL
Intervention: S‐WEIGHT (low load, high repetition weight training)
Number of subjects: 20

Group type: COMPARATOR
Intervention: S‐CORE (core focused fusion classes)
Number of subjects: 20
Study: 26083474

Group type: EXPERIMENTAL
Intervention: 10-Valent Pneumococcal Non-Typeable Haemophilus influenza Protein D Conjugate Vaccine (PHiD-CV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hepatitis A vaccine
Number of subjects: 60
Study: 22985340

Group type: EXPERIMENTAL
Intervention: Participants who wrote about a past guilt-inducing event
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants who wrote about feeling sad or a neutral event
Number of subjects: 0
Study: 22166754

Group type: EXPERIMENTAL
Intervention: High PUFA diet
Number of subjects: 141

Group type: COMPARATOR
Intervention: Low PUFA diet
Number of subjects: 141
Study: 19254599

Group type: EXPERIMENTAL
Intervention: Self-management (SM) intervention
Number of subjects: 522
Study: 16466811

Group type: EXPERIMENTAL
Intervention: TIVA with propofol (Group I)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group II)
Number of subjects: 25
Study: 15054015

Group type: COMPARATOR
Intervention: Safe Dates program
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Safe Dates program with booster
Number of subjects: 10
Study: 11332239

Group type: EXPERIMENTAL
Intervention: Rofecoxib (maximum single dose 12.5 mg, cumulative dose 25 mg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 9596392

Group type: EXPERIMENTAL
Intervention: Cold bath (24 degrees C) for 20 minutes
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 14
Study: 7889606

Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection after fine needle aspiration (Group 2)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fine needle aspiration alone (Group 1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection (Group 3)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fluid aspiration alone (Group 1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection (Group 2)
Number of subjects: 52
Study: 3272748

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30690478

Group type: EXPERIMENTAL
Intervention: MSI identification of cryptic species
Number of subjects: 5108

Group type: EXPERIMENTAL
Intervention: MSI identification of noncryptic species
Number of subjects: 5108
Study: 26442473

Group type: EXPERIMENTAL
Intervention: Treadmill exercise (T) at 65% VO2 R for 30 minutes
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cycle exercise (C) at 65% VO2 R for 30 minutes
Number of subjects: 14
Study: 26481907

Group type: EXPERIMENTAL
Intervention: Active right dorsolateral prefrontal cortex (dlPFC) stimulation with rTMS (10 Hz)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 38
Study: 23732514

Group type: EXPERIMENTAL
Intervention: Partner-with-encouragement (n=55)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Partner-without-encouragement (n=25)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Individual (n=35)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Online teams (n=80)
Number of subjects: 115
Study: 21730079

Group type: EXPERIMENTAL
Intervention: Two-step hand hygiene process (hand hygiene education plus institutionally provided alcohol-based hand sanitizer)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 527
Study: 19593996

Group type: EXPERIMENTAL
Intervention: Short-period sperm-oocyte coincubation with early rescue ICSI
Number of subjects: 115

Group type: COMPARATOR
Intervention: Overnight fertilization
Number of subjects: 115
Study: 17175328

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 39
Study: 12855921

Group type: EXPERIMENTAL
Intervention: Transdermal ketoprofen applied TID to quadriceps
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo cream applied TID to quadriceps
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transdermal ketoprofen
Number of subjects: 32
Study: 10911654

Group type: EXPERIMENTAL
Intervention: Icodextrin (I) solution
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Icodextrin (I) solution during peritonitis (P)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Glucose (G) solution
Number of subjects: 38

Group type: COMPARATOR
Intervention: Glucose (G) solution during peritonitis (P)
Number of subjects: 38
Study: 8616558

Group type: EXPERIMENTAL
Intervention: Slow inspiration
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Breath hold
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fast inspiration
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aerosolized bronchodilator
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lung elastic recoil pressure (Pel Blow)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Breath hold time
Number of subjects: 15
Study: 1477688

Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl (P/F)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Midazolam-fentanyl (M/F)
Number of subjects: 75
Study: 6088396

Group type: EXPERIMENTAL
Intervention: Fresh human milk (200 ml per day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Formula diet (control group)
Number of subjects: 30
Study: 31158560

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) plus standardised medical care
Number of subjects: 368

Group type: COMPARATOR
Intervention: Standardised medical care alone
Number of subjects: 368
Study: 30374788

Group type: EXPERIMENTAL
Intervention: Lumbar spine bone mineral density (LS‐BMD)
Number of subjects: 5214

Group type: EXPERIMENTAL
Intervention: Bone mineral apparent density (LS‐BMAD)
Number of subjects: 5214
Study: 27515301

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 14
Study: 24659069

Group type: COMPARATOR
Intervention: Intravenous sedation (IVS) with midazolam/fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Axillary nerve block (ANB)
Number of subjects: 60
Study: 22207530

Group type: EXPERIMENTAL
Intervention: Floseal (FS)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Electrocautery (EC)
Number of subjects: 176
Study: 20097931

Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg
Number of subjects: 1793

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg
Number of subjects: 1793

Group type: EXPERIMENTAL
Intervention: Tocilizumab (4 or 8 mg/kg)
Number of subjects: 1793